Format

Send to

Choose Destination
Future Oncol. 2017 May;13(12):1115-1127. doi: 10.2217/fon-2016-0468. Epub 2017 Jan 23.

Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.

Li D1,2, Fu Q3, Li M1,2, Li J1,2, Yin C1,2, Zhao J1,2, Li F1,2,4,5.

Author information

1
Department of Pathology & Key Laboratory for Xinjiang Endemic & Ethnic Diseases, Shihezi University School of Medicine, Shihezi, Xinjiang, China.
2
Department of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang, China.
3
Department of Hepatobiliary Pancreatic Surgery, People's Hospital of Zhengzhou University, Zhengzhou University School of Medicine, Zhengzhou, Henan, China.
4
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
5
Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Abstract

AIM:

This meta-analysis aimed to document the impact of primary tumor site on anti-EGFR monoclonal antibody (mAb) benefit in metastatic colorectal cancer.

MATERIALS & METHODS:

Tumors with metastatic left-sided colorectal cancer (LCC) were compared with tumors with metastatic right-sided colon cancer (RCC) with respect to anti-EGFR mAb objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) benefit.

RESULTS:

Comparing LCC with RCC, LCC was found to have significantly superior anti-EGFR mAb ORR (p < 0.00001), OS (p < 0.00001) and PFS (p < 0.00001) benefit. Additionally, anti-EGFR mAb therapy significantly improved both OS and PFS for LCC compared with no anti-EGFR mAb therapy, but not for RCC. The test of interaction was also apparent for OS (p = 0.0002) and PFS (p = 0.0002).

CONCLUSION:

This meta-analysis demonstrated that LCC had markedly superior anti-EGFR mAb treatment benefit compared with RCC.

KEYWORDS:

anti-EGFR mAb; left-sided; mCRC; meta-analysis; predictive; prognostic; right-sided

PMID:
28110551
DOI:
10.2217/fon-2016-0468
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center